Ekso Bionics Holdings, Inc. — FY2017 Form 10-K
Entity and period: The supplied filing is for Ekso Bionics Holdings, Inc., not Chronoscale Holdings Corp. It reports the fiscal year ended December 31, 2017; the filing also provides unaudited fourth-quarter results. Unless noted, amounts below are U.S. dollars.
Business context
Ekso designs, develops and sells wearable exoskeletons for medical rehabilitation and industrial applications, and provides engineering services. Its main medical product is the Ekso GT, used in rehabilitation for certain patients with stroke or spinal cord injury. Industrial products include EksoZeroG and EksoVest. Management described the business as early-stage commercialization and focused on broader adoption, clinical evidence, industrial sales and product development.
Financial results and liquidity
| Metric | FY2017 | FY2016 |
|---|---|---|
| Revenue | $7.35 million | $14.22 million |
| Gross profit / margin | $2.07 million / 28.1% | $2.95 million / 20.7% |
| Operating loss | $31.61 million | $27.59 million |
| Net loss | $29.12 million | $23.47 million |
| Net loss per share, basic | $0.82 | $1.87 |
| Cash used in operating activities | $31.23 million | $25.00 million |
| Cash at year-end | $27.81 million | $16.85 million |
| Note payable, net | $6.97 million | $6.79 million |
FY2017 revenue fell 48%, mainly because FY2016 included $6.5 million of previously deferred medical-device revenue recognized after a change in accounting estimate; increased device and industrial sales partly offset that effect. Engineering-services revenue dropped to $38,000 from $787,000, with no substantial engineering projects in 2017. Medical-device revenue was $5.83 million and industrial revenue was $1.48 million in 2017.
Gross profit declined 30%; the prior-year comparison included $2.4 million of gross profit from the accounting change. Sales and marketing expense rose 20% to $13.16 million and R&D expense rose 7% to $9.48 million; G&A was roughly flat at $10.72 million. The 2017 net loss included a $3.91 million non-cash warrant revaluation gain and a $1.07 million loss on warrant repurchase. These items affected reported earnings but do not represent operating cash generation.
Year-end current assets were $34.94 million and current liabilities were $9.17 million. The company reported $3.22 million of contractual payments due within one year, including term-loan payments, leases and a capital lease. Its $7.0 million term loan bears interest at 30-day U.S. LIBOR plus 5.41%, is secured by substantially all assets other than intellectual property, and matures January 2021. The company reported covenant compliance at year-end.
Financing activities provided $42.57 million in 2017, principally from an April equity offering and an August rights offering and related private placement. Outstanding common shares were 59.94 million at year-end, versus 21.89 million a year earlier; the filing reported 60.22 million shares outstanding as of March 2, 2018.
Fourth-quarter 2017 revenue was $2.45 million, gross profit $777,000 and net loss $8.98 million. Revenue was higher than in each of the first three quarters, but the quarterly net loss was also the largest of 2017.
Material changes and management outlook
- In May 2017, the company reduced its workforce by about 27 employees; it recorded $659,000 in restructuring expense and completed the plan by the end of the second quarter.
- Management said year-end cash was sufficient to fund operations beyond the one-year look-forward period from issuance of the financial statements. Elsewhere, the filing states the company expected resources to last “well into 2019.” Management also said significant additional financing may be required; availability and terms are uncertain.
- For 2018, stated priorities included expanding rehabilitation adoption and clinical evidence, continuing the WISE spinal-cord-injury study, expanding selectively in Asia, developing home-use medical devices, and rolling out industrial products. The filing gives no quantified revenue, earnings or cash-flow guidance.
- The company had shipped more than 275 Ekso GT units to nearly 200 rehabilitation facilities or customers worldwide as of February 1, 2018. Reimbursement, clinical evidence and lengthy institutional sales cycles remain important adoption constraints.
Risks, contingencies and unusual items
- The company has a continuing history of losses and negative operating cash flows, with an accumulated deficit of $144.2 million. Additional financing may be needed and could dilute shareholders; failure to obtain funding could require spending cuts or curtailment of operations.
- Revenue comparisons are affected by the 2016 accounting-estimate change. Warrant fair-value gains are non-cash and depend partly on share-price movements.
- Medical-device adoption depends on clinical results, regulatory compliance and payer coverage or reimbursement. The filing notes that existing outpatient physical-therapy codes provide modest reimbursement, but no specific CPT code then described robotic exoskeletons.
- Two securities class actions and a shareholder derivative action were filed in early 2018 relating to alleged proxy-statement inaccuracies and the previously disclosed internal-control weakness. The company denied the allegations and said it intended to defend the suits. Shareholders were to vote again on the authorized-share amendment at the 2018 annual meeting.
- Management and the auditor concluded internal control over financial reporting was effective as of December 31, 2017, following remediation of a material weakness identified for 2016. The auditor issued unqualified opinions on the financial statements and internal controls.
- Management announced the CEO’s resignation in March 2018 and Jack Peurach’s appointment as CEO. The filing also disclosed severance and equity-vesting arrangements for departing executives.
- The Tax Cuts and Jobs Act reduced the federal corporate tax rate; the company recorded a corresponding deferred-tax remeasurement offset by its valuation allowance. It reported no net deferred tax asset because realization was not considered more likely than not.
Key facts for investors to verify
- Reconcile the 2016 revenue and gross-profit comparison for the $6.5 million deferred-revenue recognition and assess underlying device and industrial sales trends.
- Evaluate cash burn against year-end cash, debt maturities, the loan’s liquidity covenant and management’s financing assumptions; clarify the differing cash-runway descriptions in the filing.
- Track clinical-trial progress, reimbursement pathways, customer adoption and the economics of industrial products.
- Review dilution and governance implications of the 2017 offerings, outstanding warrants and options, and the renewed shareholder votes on authorized shares and the equity plan.
- Monitor the proxy-related litigation, executive departures and the sustained effectiveness of remediated financial-reporting controls.